ATP6V1D | ATPase, H+ transporting, lysosomal 34kDa, V1 subunit D | | | | | | Expressed in all |
ATP6V1E1 | ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E1 | Plasma proteins Transporters
| | | | | Expressed in all |
ATP6V1E2 | ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E2 | | | | | | Expressed in all |
ATP6V1F | ATPase, H+ transporting, lysosomal 14kDa, V1 subunit F | Transporters
| | | | | Expressed in all |
ATP6V1G1 | ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G1 | Plasma proteins Transporters
| | | | | Expressed in all |
ATP6V1G2 | ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G2 | | | | | | Tissue enriched |
ATP6V1G3 | ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G3 | Transporters
| | | | | Tissue enriched |
ATP6V1H | ATPase, H+ transporting, lysosomal 50/57kDa, V1 subunit H | Transporters
| | | | | Expressed in all |
BAIAP2L1 | BAI1-associated protein 2-like 1 | | | | | | Mixed |
BCAR1 | Breast cancer anti-estrogen resistance 1 | Plasma proteins Predicted secreted proteins
| | | | | Mixed |
BDH1 | 3-hydroxybutyrate dehydrogenase, type 1 | Candidate cardiovascular disease genes Enzymes Mitochondrial proteins
| | | | | Expressed in all |
BMP8A | Bone morphogenetic protein 8a | Predicted secreted proteins
| | | | | Tissue enriched |
BRSK2 | BR serine/threonine kinase 2 | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
BSCL2 | Berardinelli-Seip congenital lipodystrophy 2 (seipin) | Disease related genes Predicted membrane proteins
| | | | | Expressed in all |
CAB39 | Calcium binding protein 39 | Plasma proteins
| | | | | Expressed in all |
CAB39L | Calcium binding protein 39-like | Plasma proteins
| | | | | Expressed in all |
CACNA1A | Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1D | Calcium channel, voltage-dependent, L type, alpha 1D subunit | Cancer-related genes Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Mixed |
CACNA2D2 | Calcium channel, voltage-dependent, alpha 2/delta subunit 2 | FDA approved drug targets Transporters
| | | | | Tissue enriched |
CAMK2G | Calcium/calmodulin-dependent protein kinase II gamma | Enzymes Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
CARTPT | CART prepropeptide | FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enriched |
CASR | Calcium-sensing receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CD38 | CD38 molecule | Cancer-related genes CD markers Enzymes
| | | | | Mixed |
CDK1 | Cyclin-dependent kinase 1 | Cancer-related genes Enzymes Plasma proteins
| | | | | Mixed |
CDK16 | Cyclin-dependent kinase 16 | Enzymes
| | | | | Expressed in all |
CEP19 | Centrosomal protein 19kDa | | | | | | Mixed |
CHRM3 | Cholinergic receptor, muscarinic 3 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
CITED1 | Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 1 | | | | | | Tissue enriched |
CNR1 | Cannabinoid receptor 1 (brain) | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CPEB1 | Cytoplasmic polyadenylation element binding protein 1 | | | | | | Tissue enhanced |
CPEB2 | Cytoplasmic polyadenylation element binding protein 2 | | | | | | Expressed in all |
CPLX1 | Complexin 1 | | | | | | Tissue enriched |
CPLX3 | Complexin 3 | | | | | | Tissue enhanced |
CPT1A | Carnitine palmitoyltransferase 1A (liver) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
CRH | Corticotropin releasing hormone | Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
CRK | V-crk avian sarcoma virus CT10 oncogene homolog | | | | | | Expressed in all |
CYB5R4 | Cytochrome b5 reductase 4 | Enzymes
| | | | | Expressed in all |
DOC2B | Double C2-like domains, beta | | | | | | Mixed |
DOK2 | Docking protein 2, 56kDa | | | | | | Mixed |
DOK3 | Docking protein 3 | | | | | | Expressed in all |
DOK4 | Docking protein 4 | | | | | | Expressed in all |
DOK6 | Docking protein 6 | | | | | | Mixed |
DOK7 | Docking protein 7 | Disease related genes Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
DRD2 | Dopamine receptor D2 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
EEF2K | Eukaryotic elongation factor-2 kinase | Enzymes
| | | | | Expressed in all |
EFNA5 | Ephrin-A5 | Cancer-related genes Predicted membrane proteins RAS pathway related proteins
| | | | | Mixed |
EGR2 | Early growth response 2 | Disease related genes Transcription factors
| | | | | Tissue enhanced |
EIF4B | Eukaryotic translation initiation factor 4B | | | | | | Expressed in all |
EIF4E | Eukaryotic translation initiation factor 4E | Cancer-related genes Disease related genes Plasma proteins
| | | | | Expressed in all |
EIF4G1 | Eukaryotic translation initiation factor 4 gamma, 1 | Cancer-related genes Disease related genes Plasma proteins
| | | | | Expressed in all |